Feed PBH
PB

Prestige Consumer Healthcare

PBH · NYSE

$47.25 +0.95% (+$0.45)
1M -10.03%
Market Cap $2.22B
P/E Ratio 12.89x
Div. Yield -
ROE 9.22%

Bulios Fair Price

$45.53

3.6% downside

Current Price

$47.25

Undervalued Fair Value Overvalued

According to Bulios Fair Price, PBH is currently trading close to its fair value. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
5/9
Valuation
83 /100
Cheap
P/FCF 9.42x
P/S 2.01x
P/B 1.16x
Growth
32 /100
Declining
FCF growth 3.55%
Book val. growth 9.26%
Rev. growth 1.17%
Profitability
98 /100
Strong
Net margin 15.57%
Op. margin 26.26%
FCF margin 21.30%
Quality
31 /100
Poor
ROE 9.22%
ROA 3.77%
Asset turnover 0.24x
Debt
42 /100
Moderate
Current ratio 3.23x
Int. coverage 6.08x
Net debt/EBITDA 6.31x
Stability
46 /100
Moderate
Rev. volatility 2.82%
EPS volatility 205.46%
Profitable years 3

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PBH
Online

About the company

Prestige Consumer Healthcare Inc. is a U.S.-based company specializing in the manufacturing and distribution of over-the-counter healthcare products. Founded in 1996 and headquartered in Irvington, New York, the company focuses on a wide range of products, including pain relief medications, dietary supplements, oral care products, skincare treatments, and other wellness products. Prestige Consumer Healthcare has a strong market presence and sells its products through various distribution channels, including retail and online sales.

Sector

Healthcare

Industry

Medical - Pharmaceuticals

CEO

Ronald Lombardi

Employees

890

Headquarters

Tarrytown

Upcoming events

05 NOV

Earnings

Upcoming earnings report

44d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.